Loading stock data…
IDEAYA Biosciences (IDYA)
$36.55-0.19 (-0.52%)
Market ClosedLast close Jun 29
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
IDEAYA Biosciences, Inc. in the Healthcare sector is trading at $36.55 with a market capitalization of $2.9B. Wall Street consensus targets $52.79 (14 analysts), implying a +44.4% move over the next 12 months. The stock is currently near its 52-week high of $39.28, remaining 15.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +44.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.56M↓ | $10.88M↓ | $207.83M | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$108.54M↓ | -$94.57M↓ | $108.45M↑ | -$88.81M↓ | -$84.39M |
| Net Income | -$98.54M↓ | -$83.27M↓ | $119.24M↑ | -$77.49M↓ | -$72.18M |
Peer Comparison
JNJUNHPFE
Fundamentals
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.88B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-14.94%
Volume
Today's trading volume
983,744
Recent News
Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy Study
IDEAYA Biosciences Inc. (NASDAQ:IDYA) is one of the 10 best AI driven biotech stocks to invest in. On June 3, in order to study the safety and efficacy of IDE892 in conjunction with Roche’s pan-RAS inhibitor, RG6505, in patients with MTAP-deleted pancreatic ductal adenocarcinoma, Ideaya Biosciences Inc. (NASDAQ:IDYA) and Roche (RHHBY) formed a clinical partnership. […]
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results
Tango Therapeutics shares rallied on Monday after recording impressive results for its pancreatic cancer drug. Here’s how you should play TNGX stock at current levels.
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Amid Inflation Data
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively trad
What IDEAYA Biosciences (IDYA)'s Darovasertib Phase 2/3 Win and Roche Deal Mean For Shareholders
IDEAYA Biosciences recently reported full Phase 2/3 OptimUM-02 data showing its darovasertib and crizotinib combination improved progression-free survival and response rates versus standard therapies in first-line HLA*A2:01 negative metastatic uveal melanoma, while also advancing an NDA under the FDA’s Real-time Oncology Review program. On top of this, IDEAYA entered a clinical collaboration with Roche to test its PRMT5 inhibitor IDE892 with Roche’s pan-RAS inhibitor RG6505, underscoring...
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit
IDEAYA Biosciences (NASDAQ:IDYA) executives highlighted recent clinical progress across the company’s oncology pipeline during a fireside chat at TD Cowen’s seventh annual Oncology Innovation Summit, with the discussion focused primarily on darovasertib combinations in uveal melanoma and several ear